Tuesday, 17 November 2026 Every SEC filing alert, by company
ALFA USA Filings Every alert, straight from SEC EDGAR
News
Financial Results · Q3 2026

Nurix Therapeutics Q3 2026 Results: Turns Profitable, Net Income $550M

Nurix Therapeutics reported a significant swing to profitability for the quarter ended August 31, 2026, with net income of $549.8 million compared to a net loss of $86.4 million in the prior year, primarily driven by $653.2 million in license revenue. The company's cash position strengthened significantly to $720.2 million, up from $247.0 million at the end of fiscal 2025.

Q3 2026 at a glance · $ million
MetricQ3 2026Q3 2025
Revenue673.17.9
Profit before tax563.4-86.4
Net income549.8-86.4
EPS (diluted, $ a share)$4.73$-1.03

A dash means the filing did not report that period. Growth is not shown when either period was a loss. Figures from the filing's XBRL data.

Growth and margins
Revenue, year on year+8426.3%
Operating margin83.1%
Source

10-Q filed with the SEC, NASDAQ: NRIX. Figures from the filing's XBRL data; summary written with AI assistance from the filing.

Read the filing ↗

Nurix Therapeutics, Inc.: key numbers

Share price
$14.73Close, Nov 16
Market cap
$1.61B
Shares outstanding
109.25MLatest SEC cover page
Sector
Life Sciences
Industry
Pharmaceutical PreparationsSIC 2834

Today's reference numbers, updated daily. Not a valuation or a recommendation.

More from Nurix Therapeutics, Inc.

All →
5:06 PM ET Form 4
Insider Selling

Nurix Therapeutics CFO Houte Hans van Sells $74.6K of Stock

Houte Hans van, CFO, sold 4,769 shares of Nurix Therapeutics, Inc. at $15.38 to $16.20 a share (average $15.63) in 2 transactions, worth $74.6K in total on Nov 4, 2026. Shares held after the trade: 42,745 (-3.3%).

Value
$74.6K
Shares
4,769
Average price
$15.63
Role
CFO
Holding change
-3.3%
Trade date
Nov 4, 2026
5:03 PM ET Form 4
Insider Selling

Nurix Therapeutics CLO Christine Ring Sells $432K of Stock

Christine Ring, CLO, sold 16,715 shares of Nurix Therapeutics, Inc. at $25.74 to $26.76 a share (average $25.84) in 3 transactions, worth $432K in total between Nov 2, 2026 and Nov 3, 2026. Shares held after the trade: 4,406 (-58.1%).

Value
$432K
Shares
16,715
Average price
$25.84
Role
CLO
Holding change
-58.1%
Trade date
Nov 2, 2026 to Nov 3, 2026
4:02 PM ET 8-K
Deal Termination

Nurix Therapeutics Deal Termination with Sanofi S.A.

Nurix Therapeutics announced that its collaboration partner Sanofi has decided to discontinue the Phase 1 clinical trial and terminate the SAR448272 oral STAT6 degrader program. As a result, Nurix will no longer be eligible for future development, regulatory, or commercial milestone payments and royalties specifically for this program, though other licensed programs under the Sanofi collaboration remain active.

Counterparty
Sanofi S.A.
7:47 PM ET Form 4
Insider Selling

Nurix Therapeutics CFO Houte Hans van Sells $74.5K of Stock

Houte Hans van, CFO, sold 2,834 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $74.5K in total on Oct 30, 2026. Shares held after the trade: 47,514 (-5.6%).

Value
$74.5K
Shares
2,834
Price
$26.28
Role
CFO
Holding change
-5.6%
Trade date
Oct 30, 2026
7:45 PM ET Form 4
Insider Selling

Nurix Therapeutics CLO Christine Ring Sells $104K of Stock

Christine Ring, CLO, sold 3,957 shares of Nurix Therapeutics, Inc. at $26.28 a share, worth $104K in total on Oct 30, 2026. Shares held after the trade: 15,335 (-20.5%).

Value
$104K
Shares
3,957
Price
$26.28
Role
CLO
Holding change
-20.5%
Trade date
Oct 30, 2026
7:42 PM ET Form 4
Insider Selling

Nurix Therapeutics CSO Gwenn Hansen Sells $143K of Stock

Gwenn Hansen, CSO, sold 5,409 shares of Nurix Therapeutics, Inc. at $26.28 to $26.80 a share (average $26.42) in 2 transactions, worth $143K in total between Oct 30, 2026 and Nov 2, 2026. Shares held after the trade: 123,452 (-1.2%).

Value
$143K
Shares
5,409
Average price
$26.42
Role
CSO
Holding change
-1.2%
Trade date
Oct 30, 2026 to Nov 2, 2026

Get Alerts

Get ALFA Finder alerts first

Real-time SEC filing alerts for US stocks are launching soon. Leave your details and we'll tell you the moment they go live.